## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.4% in lower entry zone (4.0-10.0%), top quartile (88th pct) cross-sectional ranking. Short-term MRS_5 (0.5%) confirms momentum alignment. Outperforming sector by 11.0%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($24.99)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. ACADIA Pharmaceuticals (ACAD) Receives a Buy from UBS**
- Source: The Globe and Mail | 20251207T052144 | Bullish | Relevance: 99%
-  UBS analyst Ashwani Verma has maintained a Buy rating on ACADIA Pharmaceuticals (ACAD) with a $35.00 price target, citing strong financial performance and strategic growth. The company reported significant increases in quarterly revenue and net profit. Despite negative insider sentiment from recent share sales, other analysts like Citi also issued Buy ratings, while Mizuho Securities maintained a Hold.

**2. Norges Bank Invests $31.68 Million in ACADIA Pharmaceuticals Inc. $ACAD**
- Source: MarketBeat | 20251208T110938 | Bullish | Relevance: 98%
- Norges Bank has acquired a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), purchasing 1,468,647 shares valued at approximately $31.68 million in the second quarter. This investment gives Norges Bank about 0.87% ownership of the biopharmaceutical company. The news follows ACADIA's strong Q3 earnings, where it exceeded analyst estimates with an EPS of $0.42 and revenue of $278.6 million.

**3. Marshall Wace LLP Purchases 1,639,315 Shares of ACADIA Pharmaceuticals Inc. $ACAD**
- Source: MarketBeat | 20251207T112144 | Bullish | Relevance: 98%
-  Marshall Wace LLP significantly increased its stake in ACADIA Pharmaceuticals (NASDAQ:ACAD) by purchasing 1,639,315 additional shares in Q2, bringing its total holdings to 1,969,711 shares valued at approximately $42.49 million. Despite some insider selling, institutional investors own a substantial portion of the company, which recently exceeded quarterly EPS estimates and saw an 11.3% year-over-year revenue increase. Wall Street analysts maintain a "Moderate Buy" consensus rating for ACADIA Pharmaceuticals with a target price of around $28.89.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Mizuho | $29 | $24 | +21% |
| 2025-11-17 | JP Morgan | $31 | $33 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Mizuho | main | Neutral |
| 2025-11-17 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 4 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.8%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.5B |
| Beta | 0.67 |
| 52W Range | $13.40 - $27.73 |
| Short Interest | 8.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 33.1 |
| Current P/E | 33.0 |
| YoY Growth | -0.5% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at 6.4% (minimal 5-day change). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 88th percentile. MRS_5 at 0.5% confirms short-term momentum alignment. AM_20 at 8.7% shows strong absolute momentum above own 20MA. Outperforming sector by 11.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.43% (CS: 88) | Strong |
| RSI_14 | 69.4 | Neutral |
| MACD Histogram | 0.25 | Bullish |
| vs SMA20 | 1.087x | Above |
| vs SMA50 | 1.176x | Above |
| vs SMA200 | 1.272x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $26.89
- **Stop Loss:** $24.99 (7.1% risk)
- **Target:** $29.74 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 157
- **Position Value:** $4,221.73
- **Portfolio %:** 4.22%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*